Cisplatin Induced Tinnitus, Relapsed Germ Cell Cancer
Conditions
Keywords
relapsed germ cell cancer, cisplatin induced tinnitus, music therapy, germ cell cancer
Brief summary
Pilot study evaluating the feasibility of recruitment, retention, and compliance to a modified Heidelberg Model of Neuro-Music Therapy (mHNMT) in patients with Cisplatin-induced Tinnitus and relapsed Germ Cell Cancer (rGCC).
Detailed description
This is a prospective, interventional pilot study that plans to enroll 15 patients who are receiving salvage high dose chemo and bone marrow transplant for relapsed Germ cell Cancer (rGCC). Patients will be asked to go through a series of surveys and screening procedures to determine eligibility. Once enrolled, patients will receive music therapy while they are being treated either inpatient or outpatient for their standard of care treatments. Primary Objective To evaluate the feasibility of recruitment, retention, and compliance to a mHNMT in patients with CIT and rGCC admitted to BMT service to undergo salvage high-dose chemotherapy with tandem bone marrow rescue. Secondary Objectives To estimate the effects of mHNMT on severity of CIT, associated distress, anxiety, depression, fatigue, benefit findings, sleep, and audiometry measures and assess number of times homework completed.
Interventions
BEHAVIORALModified Heidelberg Model of Neuro-Music Therapy
6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
Sponsors
Indiana University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Study will enroll 15 subjects to a twice a week Music Therapy intervention (modified Heidelberg Model of Neuro-Music Therapy) for 3 weeks (6 sessions total).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years old at the time of informed consent. 2. English speaking. 3. Ability to provide written informed consent and HIPAA authorization 4. Confirmed diagnosis of CIT via a score on the TFI of 26 or greater. 5. Personal history of rGCC. 6. Previous exposure to cisplatin. 7. Admitted to BMT service to undergo HDC-tBMR for the first time. (Because this is a feasibility study, a minimum number of MT sessions will not be required). 8. Agrees not to receive music therapy outside of study.
Exclusion criteria
1. Severe hearing impairment greater than 60 dB HL in the region of the center tinnitus frequency 2. Patient's tinnitus can not be pitch matched. 3. Clinical diagnosis of severe mental disorder or psychiatric or neurological disease such as psychosis, epilepsy, Parkinson's disease, dementia, alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recruitment feasibility | 30 days | The ability to enroll at least 50% of approached subjects. |
| Retention feasibility | from the start of intervention until last subject completes intervention (i.e. up to 2 years) | The ability to successfully retain 60% of enrolled subjects. |
| Compliance and fidelity feasibility | from the start of intervention until last subject completes intervention (i.e. up to 2 years) | The ability to deliver over 90% of planned intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects of intervention on depression determined by scores on Hospital Anxiety and Depression Scale | Baseline, day +50, day +100, and day +270 | Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The HADS uses a scale and therefore the data returned from the HADS is ordinal. |
| Effects of intervention on benefit findings determined by scores on The Benefit Finding Scale | Baseline, day +50, day +100, and day +270 | Uses a 5-point Likert scoring method from 1 = Not at all to 5 = Extremely. |
| Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Adult Short Form | Baseline, day +50, day +100, and day +270 | Use a 5-point Likert scale and employ 7-day recall. Higher scores indicate higher levels of fatigue. Scores are standardized (M = 50, SD = 10) |
| Effects of intervention on severity of Cisplatin Induced Tinnitus determined by scores on the Tinnitus Functional Index | Baseline, day +50, day +100, and day +270 | The Tinnitus Functional Index (TFI) has eight subscales that address the intrusiveness of tinnitus, the sense of control the patient has, cognitive interference, sleep disturbance, auditory issues, relaxation issues, quality of life, and emotional distress. Minimum value is 1 and maximum value is 10. A higher score indicates worse tinnitus. A mean score of 25 or less than 25 indicates relatively mild tinnitus and little or need for intervention. A mean score ranging from 25-50 indicates significant problems with tinnitus and a possible need for intervention. A mean score of 50 or greater indicates tinnitus severe enough to qualify for more aggressive intervention. |
| Number of times homework completed | Each day of intervention until study completion, about 3 weeks | This will be assessed each day of the intervention and captured using the Actiwatch Spectrum Pro and summed over the entire intervention period. |
| Audiometric evaluation | Baseline and day +270 (+/- 90 days) | The Pure-tone hearing threshold audiometry (PTA) measures and classifies hearing loss into three levels: \<25 dB (normal hearing); ≥25 dB \<40 dB (mild hearing impairment); and ≥40 dB (moderate-to-severe hearing impairment). PTA will be measured in a soundproofing booth using an audiometer (SA 203, Entomed, Sweden), and include frequencies of 500, 1000, 2000, 3000, 4000, and 6000 Hz in both ears in accordance with the American National Standards Institute (ANSI) standard. The hearing threshold will be defined as the mean hearing threshold of the better ear on PTA tests at 500, 1000, 2000, and 4000 Hz. Hearing loss in this study will be defined as follows: \<25 dB (normal hearing), ≥25 dB and \<40 dB (mild hearing loss), and ≥40 dB (moderate-to-severe hearing loss). |
| Number of hours asleep | Up to 3 weeks | Actiwatch Spectrum Pro watch. Sleep parameters will be computed using Actiware® software. The sleep parameters produced include total sleep time, sleep latency (minutes until sleep onset), sleep efficiency, frequency and duration of awakenings after sleep onset (WASO), and number of awakenings. These Sleep variables will be scored for each 24-hour period, and averages over the course of use will be computed for nighttime sleep alone and nighttime sleep plus daytime naps to be combined into epochs for assessment. |
| Effects of intervention on associated distress determined by scores on the Tinnitus Questionnaire | Baseline, day +50, day +100, and day +270 | For each item, individuals indicate the level of agreement by answering; not true (score 0), partly true (score 1), or true (score 2). A three point scale limits its utility as an outcome measure. Total scores range from 0-82, with higher scores indicating more distressing tinnitus. |
| Effects of intervention on anxiety determined by scores on the Impact of Events Scale | Baseline, day +50, day +100, and day +270 | A 22-item self-report measure that assesses subjective distress caused by traumatic events on a scale from 0-4, where 0 is not at all, and 4 is extremely. A higher score indicates increased anxiety. |
Countries
United States
Outcome results
None listed